Loading stock data…
OABI
$1.40+0.01 (+0.72%)
Market ClosedLast close May 1
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OmniAb, Inc. in the Healthcare sector is trading at $1.40. The stock is currently near its 52-week low of $1.22, remaining 20.0% below its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why OABI maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.40
Potential Upside
5%
Whystock Fair Value$1.47
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$217.17M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.87
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-7.21%
Volume
Today's trading volume
510,583
Recent News
Bullish OmniAb Insiders Loaded Up On US$1.28m Of Stock
Over the last year, a good number of insiders have significantly increased their holdings in OmniAb, Inc. ( NASDAQ:OABI...
OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026
OmniAb Inc. (NASDAQ:OABI) is one of the 8 Best Life Sciences Penny Stocks to Buy. On March 5, guidance for 2026 revenues for OmniAb Inc. (NASDAQ:OABI) was estimated at $25 million to $30 million, driven by growth in the partner pipeline and launches of the OmniUltra and xPloration products. According to Matthew Foehr, CEO of […]
Here Is Why You Should Not Ignore OmniAb Inc. (OABI)
OmniAb Inc. (NASDAQ:OABI) is one of the 10 best penny stocks that could triple your money. On March 5, OmniAb Inc. (NASDAQ:OABI) reported fourth-quarter revenue of $8.4 million, coming in below consensus estimates of $9.0 million. The company closed 2025 with a growing base of 107 active partners and a growing portfolio consisting of 407 […]
OmniAb (OABI) Q4 2025 Earnings Call Transcript
By year-end, we are happy to report that we had 107 partners who are running 407 active programs. As our partner pipeline advances, certain later-stage programs are now coming into focus with the potential to drive meaningful milestone revenue and create value over time, headed toward the generation of significant future recurring royalty revenue streams. Additionally, we are building a strong foundation for our Exploration platform, which brings our high-throughput single B-cell screening capabilities directly into our partners' labs.
OmniAb, Inc. Q4 2025 Earnings Call Summary
Moby summary of OmniAb, Inc.'s Q4 2025 earnings call